A NEW STANDARD OF CARE
PreciseDx was formed with the vision to improve the multi-disciplinary team’s workflow by speeding the process of reporting tumor risk for newly diagnosed breast cancer patients. It provides the best complement to pathological tumor grading and gene expression testing for predicting the likelihood of tumor recurrence with fast, accurate, and consistent results that are much more cost effective.
PreciseDx allows cancer specialists to confidently formulate a comprehensive review of their patient's specific tumor, allowing for a more informed care plan.
94%
Negative Predictive Value*
98%
Reproducibility and Repeatability**
99%
Intra-Lab Concordance**
*Fernandez, G., Prastawa, M., A.S. et al. Breast Cancer Research 2022
**PreciseDx's "Analytical Validation of a Digital Breast Cancer Test Predicting Recurrence in Early-Stage Breast Cancer", Clinical Breast Cancer, Nov 2023
The science
We’ve long known that the secrets of cancer can be seen directly in their cellular structure, but in the past we could only look at that structure qualitatively. PreciseDx changes that.
Our study of more than 2,000 breast cancer cases* identified 7 morphologic factors that can be visualized in pathology slides and 4 clinical features that, together in our proprietary algorithm, best predict recurrence at 6 years.
The result is the Morphology Feature Array®. Applied to existing tissue slides, it produces a single Risk Score between 0 and 100, which accurately and consistently stratifies patients into two cohorts based on their tumor’s risk of recurrence.
Low risk patients have, on average, a 6% recurrence risk, while high risk patients have, on average, a recurrence risk of 24%.
Dec 9, 2024
COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence (AI)-enabled PreciseBreast™ test is equivalent to the Oncotype DX test at predicting breast cancer recurrence.
See More
Dec 9, 2024
COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence (AI)-enabled PreciseBreast™ test is equivalent to the Oncotype DX test at predicting breast cancer recurrence.
See More
Dec 6, 2024
A study from PreciseDx showed that its artificial-intelligence-guided pathology test could help predict a patient’s chances of their breast cancer returning on par with a leading genomic approach.
See More
Dec 6, 2024
A study from PreciseDx showed that its artificial-intelligence-guided pathology test could help predict a patient’s chances of their breast cancer returning on par with a leading genomic approach.
See More
Nov 20, 2024
World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio
See More
Nov 20, 2024
World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio
See More
Contact us today to learn more about PreciseBreast.
